• 1
    Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet 2000; 356: 14231430.
  • 2
    Carr A, Samaras K, Burton S et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12: F51F58.
  • 3
    WHO MONICA Project. MONICA Manual, part IV, Event Registration 1999: Ref type: internet communication.
  • 4
    Friis-Møller N, Weber R, Reiss P et al. Cardiovascular risk factors in HIV patients – association with antiretroviral therapy. Results from the DAD Study. AIDS in press (accepted for publication December 2002).
  • 5
    Anonymous. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep 1992; 41 (RR-17): 119.
  • 6
    Anderson KM, Odell PM, Wilson PW, Kannel WB. Cardiovascular disease risk profiles. Am Heart J 1991; 121 (1 Part 2): 293298.
  • 7
    McCormack JP, Levine M, Rangno RE. Primary prevention of heart disease and stroke. A simplified approach to estimating risk of events and making drug treatment decisions. CMAJ 1997; 157: 422428.
  • 8
    Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 18371847.
  • 9
    Wood D, De Backer G, Faergeman O, Graham I, Mancia G, Pyorala K. Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Atherosclerosis 1998; 140: 199270.
  • 10
    Jackson R. Updated New Zealand cardiovascular disease risk-benefit prediction guide. BMJ 2000; 320: 709710.
  • 11
    Wallis EJ, Ramsay LE, Ui Hag I Et Al. Coronary and cardiovascular risk estimation for primary prevention: validation of a new Sheffield table in the 1995 Scottish health survey population. BMJ 2000; 320: 671676.
  • 12
    Larsen CT, Dahlin J, Blackburn H et al. Prevalence and prognosis of electrocardiographic left ventricular hypertrophy, ST segment depression and negative T-wave; the Copenhagen City Heart Study. Eur Heart J 2002; 23: 315324.
  • 13
    199799 World Health Statistics Annual 2000. Ref type: internet communication.
  • 14
    Lundgren JD, Mocroft A, Gatell JM et al. A clinically prognostic scoring system for patients receiving highly active antiretroviral therapy: results from the EuroSIDA study. J Infect Dis 2002; 185: 178187.
  • 15
    Mellors JW, Munoz A, Giorgi JV et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997; 126: 946954.
  • 16
    Leport C, Saves M, Ducimetiere P et al. Coronary heart disease risk (CHD) in French HIV-infected men started on a protease inhibitor (PI)-containing regimen compared to the general population. 9th Conference on Retroviruses and Opportunistic Infections. Seattle, WA, 2002 [Abstract 697-T].
  • 17
    Egger M, Junghans C, Friis-Moller N, Lundgren JD. Highly active antiretroviral therapy and coronary heart disease: the need for perspective. AIDS 2001; 15 (Suppl. 5): S193S201.
  • 18
    Reaven G. Metabolic syndrome: pathophysiology and implications for management of cardiovascular disease. Circulation 2002; 106: 286288.
  • 19
    Tebas P, Henry K, Mondy K et al. Effect of prolonged discontinuation of successful antiretroviral therapy on CD4+ T cell decline in human immunodeficiency virus-infected patients: implications for intermittent therapeutic strategies. J Infect Dis 2002; 186: 851854.
  • 20
    Mussini C, Bugarini R, Perno CF et al. Kinetics of CD4 cells after discontinuation of antiretroviral therapy in patients with virological failure and a CD4 cell count greater than 500 cells/microl. AIDS 2002; 16: 15511554.
  • 21
    Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285: 24862497.